Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TIGIT

TIGIT

Brief Information

Name:T cell immunoglobulin and ITIM domains
Target Synonym:V-Set And Immunoglobulin Domain Containing 9,Washington University Cell Adhesion Molecule,V-Set And Transmembrane Domain Containing 3,WUCAM,DKFZp667A205,FLJ39873,V-set and immunoglobulin domain-containing protein 9,TIGIT,VSIG9,T Cell Immunoreceptor With Ig And ITIM Domains,V-Set And Transmembrane Domain-Containing Protein 3,VSIG9, VSTM3,VSTM3,T-Cell Immunoreceptor With Ig And ITIM Domains
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:23
Lastest Research Phase:Phase 3 Clinical

Licensing

Project item Indications Research phase Cooperation demands
BFS-21001 Advanced solid tumors, especially those with high expression of CD155 Complete preliminary pharmacodynamic validation Project authorization, transfer or co-development.
BBS21003 NSCLC, SCLC, multiple myeloma, liver cancer, triple negative breast cancer, pancreatic cancer, etc. Cell line was confirmed, and cell line stability study was completed. The pilot production and toxicology study is being started. Project authorization, transfer or co-development.

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
EP-131 Human TIGIT : CD155 [Biotinylated] Inhibitor Screening ELISA Kit
TIT-H52H5 Human Human TIGIT Protein, His Tag (MALS verified)
TIT-H52H5-sds
TIT-H82E6 Human Biotinylated Human TIGIT Protein, His,Avitag™ (recommended for biopanning) (MALS verified)
TIT-H82E6-structure
TIT-H82E6-sds
TIT-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque TIGIT Protein, Mouse IgG2a Fc Tag (MALS verified)
TIT-C5253-structure
TIT-C5253-sds
TIT-M5253 Mouse Mouse TIGIT Protein, Mouse IgG2a Fc Tag (MALS verified)
TIT-M5253-structure
TIT-M5253-sds
TIT-H82F3 Human Biotinylated Human TIGIT Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
TIT-H82F3-structure
TIT-H82F3-sds
TIT-C52H7 Canine Canine TIGIT Protein, His Tag (MALS verified)
TIT-C52H7-structure
TIT-C52H7-sds
TIT-H5253 Human Human TIGIT Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
TIT-H5253-structure
TIT-H5253-sds
TIT-R5259 Rabbit Rabbit TIGIT Protein, Fc Tag
TIT-R5259-structure
TIT-R5259-sds
TIT-R5258 Rat Rat TIGIT Protein, Fc Tag
TIT-R5258-structure
TIT-R5258-sds
TIT-C5254 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque TIGIT Protein, Fc Tag
TIT-C5254-structure
TIT-C5254-sds
TIT-C5223 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque TIGIT Protein, His Tag (HPLC verified)
TIT-C5223-structure
TIT-C5223-sds
TIT-C5223-hplc
TIT-H82F1 Human Biotinylated Human TIGIT Protein, Fc,Avitag™ (MALS verified)
TIT-H82F1-structure
TIT-H82F1-sds
TIT-M52E6 Mouse Mouse TIGIT Protein, His Tag (MALS verified)
TIT-M52E6-structure
TIT-M52E6-sds
TIT-M5257 Mouse Mouse TIGIT Protein, Fc Tag
TIT-M5257-structure
TIT-M5257-sds
TIT-H5254 Human Human TIGIT Protein, Fc Tag (MALS verified)
TIT-H5254-structure
TIT-H5254-sds

Part of Bioactivity data

TIT-H5253-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT used is 0.03 μg/mL (Routinely tested).

TIT-H82F1-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT is 0.03 μg/mL (Routinely tested).

TIT-H52H5-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-hTIGIT antibody captured on CM5 chip via Anti-mouse antibodies surface can bind Human TIGIT, His Tag (Cat. No. TIT-H52H5) with an affinity constant of 1.28 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

TIT-C52H7-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human CD155, Fc Tag (Cat. No. CD5-H5251) on Protein A Biosensor, can bind Canine TIGIT, His Tag (Cat. No. TIT-C52H7) with an affinity constant of 5 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name

TIGIT,VSIG9,VSTM3

Background

TIGIT has been shown to be over expressed on tumor antigen-specific CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TIL). Blockade of TIGIT led to increased cell proliferation, cytokine production, and degranulation of TA-specific CD8+ T cells and TIL CD8+ T cells, which now make it be considered as an immune checkpoint. Recently, studies have shown anti-TIGIT antibody is promising to become a cancer immunotherapy. Our ELISA kit is designed to help the discovery of anti-TIGIT therapeutic antibody.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
HH-101 HH-101 Phase 1 Clinical Huahui Health Ltd Solid tumours Details
PM-1022 PM-1022 Phase 1 Clinical Biotheus Inc Neoplasms Details
HB0030 HB0030 Phase 1 Clinical Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd Solid tumours Details
M-6223 M-6223 Emd Serono Inc, Merck Serono Details
JS-006 JS-006; TAB-006; CHS-006 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms Details
HLX-53 HLX-53 Phase 1 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Lymphoma Details
IBI-321 IBI-321 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms Details
AB-308 AB-308 Arcus Biosciences Inc Details
EOS-448 GSK-4428859; EOS-448; EOS-884448 Iteos Details
BAT-6005 BAT-6005 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours Details
SHR-2002 SHR-2002 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Neoplasms Details
ASP-8374 ASP-8374; PTZ-201 Potenza Therapeutics, Astellas Pharma Inc Details
COM-902 COM-902 Compugen Details
Tamgiblimab IBI-939 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms; Lung Neoplasms Details
SEA-TGT SGN-TGT; SEA-TGT Seattle Genetics Details
BMS-986207 BMS-986207 Bristol-Myers Squibb Company Details
AK-127 AK-127 Phase 1 Clinical Zhongshan Akeso Biopharma Co Ltd Solid tumours; Neoplasms Details
Etigilimab OMP-313M32 Phase 2 Clinical Oncomed Pharmaceuticals Inc Solid tumours; Neoplasms; Neoplasm Metastasis Details
AZD-2936 AZD-2936 Phase 2 Clinical Astrazeneca Plc Carcinoma, Non-Small-Cell Lung Details
ZG-005 ZG-005 Phase 2 Clinical Suzhou Zelgen Biopharmaceuticals Co Ltd Solid tumours Details
HLX-301 HLX-301 Phase 2 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
SHS-006(Nanjing Sanhome Pharmaceutical) SHS-006; SH-006; SH006 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Solid tumours Details
HB-0036 HB-0036 Phase 2 Clinical Huabo Biopharm Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details
Pembrolizumab/Vibostolimab MK-7684A Phase 3 Clinical Hematologic Neoplasms; Ovarian Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms; Endometrial Neoplasms; Gallbladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms Details
BAT-6021 BAT6021; BAT-6021 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours Details
PM-1021 PM1021 Phase 1 Clinical Biotheus Inc Neoplasms Details
Domvanalimab AB-154 Phase 3 Clinical Arcus Biosciences Inc, Gilead Sciences Inc Solid tumours; Glioblastoma; Lung Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Gastrointestinal Neoplasms Details
Ociperlimab BGB-A1217 Phase 3 Clinical Beigene Ltd Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Tiragolumab MTIG-7192A; RO-7092284; RG-6058 Phase 3 Clinical F. Hoffmann-La Roche Ltd Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Esophageal Squamous Cell Carcinoma; Lymphoma, Non-Hodgkin; Lymphoma, Follicular; Multiple Myeloma; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Lymphoma, B-Cell; Liver Neoplasms; Solid tumours Details
Vibostolimab MK-7684 Phase 3 Clinical Merck Sharp & Dohme Corp Solid tumours; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message